KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.

Lindsay N Carpp, Ollivier Hyrien, Youyi Fong, David Benkeser, Sanne Roels, Daniel J Stieh, Ilse Van Dromme, Griet A Van Roey, Avi Kenny, Ying Huang, Marco Carone, Adrian B McDermott, Christopher R Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Obrimpong Amoa-Awua, Manjula Basappa, Britta Flach, Bob C Lin, Christopher Moore, Mursal Naisan, Muhammed Naqvi, Sandeep Narpala, Sarah O'Connell, Allen Mueller, Leo Serebryannyy, Mike Castro, Jennifer Wang, Christos J Petropoulos, Alex Luedtke, Yiwen Lu, Chenchen Yu, Michal Juraska, Nima S Hejazi, Daniel N Wolfe, Jerald Sadoff, Glenda E Gray, Beatriz Grinsztejn, Paul A Goepfert, Linda-Gail Bekker, Aditya H Gaur, Valdilea G Veloso, April K Randhawa, Michele P Andrasik, Jenny Hendriks, Carla Truyers, An Vandebosch, Frank Struyf, Hanneke Schuitemaker, Macaya Douoguih, James G Kublin, Lawrence Corey, Kathleen M Neuzil, Dean Follmann, Richard A Koup, Ruben O Donis, Peter B Gilbert, Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team, United States Government (USG)/CoVPN Biostatistics Team

Nat Commun 15(1) 9785

PMID39532861
PMCIDPMC11557889
DOI10.1038/s41467-024-53727-y
发表日期2024-11-12
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels at 4 weeks post-Ad26.COV2.S vaccination as correlates of risk and of protection against severe-critical COVID-19 through 220 days post-vaccination in the ENSEMBLE trial (NCT04505722), constituting ~4.5 months longer follow-up than our previous correlates analysis and enabling inclusion of 42 severe-critical vaccine-breakthrough cases. Neutralizing antibody titer is a strong inverse correlate of severe-critical COVID-19, with estimated hazard ratio (HR) per 10-fold increase 0.35 (95% CI: 0.13, 0.90). In a multivariable model, HRs are 0.31 (0.11, 0.89) for neutralizing antibody titer and 1.22 (0.49, 3.02) for anti-Spike binding antibody concentration. VE against severe-critical COVID-19 rises with neutralizing antibody titer: 63.1% (95% CI: 40.0%, 77.3%) at unquantifiable [<4.8975 International Units (IU)50/ml], 85.2% (47.2%, 95.3%) at just-quantifiable (5.2 IU50/ml), and 95.1% (81.1%, 96.9%) at 90th percentile (30.2 IU50/ml). At the same titers, VE against moderate COVID-19 is 32.5% (11.8%, 48.4%), 33.9% (19.1%, 59.3%), and 60.7% (40.4%, 76.4%). Protection against moderate vs. severe disease may require higher antibody levels, and very low antibody levels and/or other immune responses may associate with protection against severe disease.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。